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In 2001, New York City implemented genotyping to its
tuberculosis (TB) control activities by using IS6110 restric-
tion fragment length polymorphism (RFLP) and spoligotyp-
ing to type isolates from culture-positive TB patients.
Results are used to identify previously unknown links
among genotypically clustered patients, unidentified sites
of transmission, and potential false-positive cultures. From
2001 to 2003, spoligotype and IS6110-based RFLP results
were obtained for 90.7% of eligible and 93.7% of submitted
isolates. Fifty-nine (2.4%) of 2,437 patient isolates had
false-positive culture results, and 205 genotype clusters
were identified, with 2–81 cases per cluster. Cluster inves-
tigations yielded 57 additional links and 17 additional sites
of transmission. Four additional TB cases were identified
as a result of case finding initiated through cluster investi-
gations. Length of unnecessary treatment decreased
among patients with false-positive cultures. 
S
ince the early 1990s, selective tuberculosis (TB) geno-
typing has been used in New York City for outbreak
investigations, to identify isolates resistant to at least iso-
niazid and rifampin (multidrug-resistant TB), and in spe-
cial studies. TB genotyping was essential to investigate
and confirm transmission in a number of settings and to
confirm or exclude laboratory contamination (1–8). A
number of programs demonstrated the utility of universal
genotyping, which influenced the development of this
service in New York City (9–16). In 2001, the New York
City Bureau of Tuberculosis Control began genotyping
isolates for every new TB case with spoligotyping and
IS6110-based restriction fragment length polymorphism
(RFLP) to improve the efficiency of TB control. Two lab-
oratories with extensive genotyping experience were
selected through a competitive bidding process. Both were
participating laboratories in the National Tuberculosis
Genotyping and Surveillance Network and had performed
genotyping for selected cases in New York City since the
early 1990s (6,17).
The objectives of universal TB genotyping were to
more rapidly and efficiently 1) determine the extent and
dynamics of ongoing transmission to focus program inter-
ventions for specific areas and populations; 2) assess TB
transmission in outbreaks to refine contact investigations;
3) identify nosocomial transmission not identified by con-
ventional methods; and 4) identify false-positive cultures
so that clinicians could be notified of diagnostic errors
quickly and prevent unnecessary TB treatment. We
describe the elements and activities required to develop
and implement real-time universal genotyping in a large
urban TB control program. 
Identifying and Obtaining Isolates 
for Genotyping
Implementation of universal genotyping in New York
City consisted, briefly, of 1) requiring submission of the
initial positive isolate, reinforced by health code amend-
ment (18,19); 2) advising all relevant laboratories and
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submission forms; 4) establishing a specimen transport
system; and 5) tracking and reviewing all submissions. In
addition, protocols were developed for surveillance of
genotype results and false-positive culture investigations,
existing patient interview forms were modified, new data-
bases were created, and program staff were informed
through special trainings and newsletters. The New York
City Department of Health and Mental Hygiene
Institutional Review Board and the associate director for
Science of the National Center for HIV, STD, and TB
Prevention, Centers for Disease Control and Prevention,
reviewed the protocols, procedures, and modified data
forms and determined that the genotyping service was not
human subjects research since it would become a routine
program activity. 
Laboratory Procedures
An additional full-time staff person was hired by the
Bureau of Tuberculosis Control to coordinate genotyping
services. Spoligotyping and RFLP, respectively, were per-
formed by the New York State Department of Health’s
Wadsworth Center in Albany, New York, and the Public
Health Research Institute in Newark, New Jersey. This
combination of genotyping methods is sensitive and spe-
cific for determining matching genotypes (20–24).
Isolates of Mycobacterium tuberculosis complex sub-
mitted to the public health laboratory from clinical labora-
tories were received on solid or liquid media and were
stored at 4°C. Liquid media were prepared (10% glycerol
in Dubos Davis broth with Tween and albumin), 1 mL of
liquid culture was injected and incubated for 3 days at
37°C and checked visually for growth. Four freeze vials (1
for spoligotyping and 3 for archiving) and 1 Lowenstein-
Jensen slant were injected. Mycobacteria in the tubes for
spoligotyping were heat-killed at 80°C for 1 hour and
mailed in biohazard containers to the Wadsworth Center.
Once appropriate growth was obtained on the Lowenstein-
Jensen slants, they were sent in a biohazard container to
the Public Health Research Institute for IS6110 RFLP
analysis. Packages were mailed on a weekly or biweekly
basis, depending on the number of isolates received.
Spoligotype analysis was performed at the Wadsworth
Center and given descriptive nomenclature according to a
standard method (25–27). DNA analysis based on IS6110
Southern blot hybridization was performed at the Public
Health Research Institute with previously described meth-
ods (28,29). To ensure good communication, a working
group of all partners in the genotyping service was formed.
Regular telephone conferences were conducted to address
issues such as quality and shipping of isolates and submis-
sion time for genotyping. 
Creation of TB Genotyping Databases
Implementing universal genotyping also required
developing a comprehensive database to monitor and man-
age information on specimen collection, shipment, and
genotyping, as well as epidemiologic information gathered
on each clustered patient. A relational database was creat-
ed by New York City TB control staff in Microsoft Access
(Microsoft Corporation, Redmond, WA, USA) that includ-
ed 1) genotyping results for isolates identified after
January 1, 2001; 2) specimen-tracking information such as
date of receipt at the public health laboratory, shipment
and reporting dates from each genotyping laboratory, and
false-positive culture investigation results; 3) clustered
patient information, such as location where each patient
spent time during the potential infectious period, locations
where TB could have been acquired in the 5 years before
diagnosis, cluster characteristics, links between patients,
and potential transmission sites; and 4) results of genotyp-
ing performed from 1990 to 2000 as part of the selective
genotyping activities (3,5,6,8,17). Queries of the database
were developed to identify cases with identical RFLP and
spoligotype results for “real-time” cluster investigation
and investigations of false-positive cultures. Quality assur-
ance exercises to test reliability of results were developed
and kept in the database. Queries are performed monthly to
identify cases for which an isolate was not submitted to the
public health laboratory. In such cases, Bureau of
Tuberculosis Control staff sends reminder letters and
makes phone calls to ensure that these isolates are
received.
Application of Universal Genotyping Data
Investigation of False-positive Culture Results
A false-positive TB culture is defined as a positive TB
culture that is not the result of culture-positive disease in a
patient but instead may be due to 1) laboratory cross-con-
tamination during specimen processing; 2) errors in collec-
tion or labeling, either on the patient ward or in the
laboratory; or 3) contamination of clinical devices, for
example, contamination of a bronchoscope during speci-
men collection. The primary goal of investigations of
false-positive cultures is to discontinue unnecessary treat-
ment in patients found to have false-positive TB cultures.
Before universal genotyping, suspected false-positive cul-
tures were investigated in 1 of 3 ways: 1) monthly review
of patients with a single positive culture; 2) request from
Bureau of Tuberculosis Control staff, including case man-
agers, department of health physicians, and epidemiolo-
gists; and 3) requests by outside providers and laboratories
to investigate cultures not consistent with the patient’s
clinical picture. With universal genotyping, an investiga-
tion can also be initiated when cases have matching
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of each other at the same facility. For these investigations,
genotype information, specimen processing, and other
information (e.g., patients hospitalized on the same floor)
are reviewed, and suspected false-positive cultures are
determined to be confirmed, unlikely, or inconclusive.
Treating physicians and clinical staff in the program are
notified of the outcome of investigations of false-positive
cultures so patient evaluation can be evaluated further and
a decision can be made on whether continued treatment is
indicated.
Genotype Cluster Investigations
A cluster investigation aims to uncover epidemiologic
links between members of a genotype cluster through sys-
tematic review of patient records and re-interviews, if
needed. We consider real-time investigation of clusters to
occur when the cluster investigation components (i.e.,
record review and re-interview) take place close to the
time the most recent case in the cluster is identified. We
defined a genotype cluster as >2 cases identified from
2001 to 2003 that had isolates with identical IS6110-based
RFLP banding pattern and spoligotype, regardless of the
number of IS6110 copies. Patients with a definite epidemi-
ologic link include those who have named each other as
contacts, have a contact in common without naming each
other as contacts, or have reported a common date range at
the same location (e.g., residence, hospital, prison, work-
place, single-room-occupancy hotel [any supervised pub-
licly or privately operated facility designed to provide
temporary living accommodations], or shelter). The com-
mon date range includes the potentially infectious period
(i.e., 3 months before start of treatment) for at least 1
patient. Patients with a probable link have spent time at the
same location (as above) during the same time frame,
exclusive of the infectious period of the patients, without
naming each other as contacts. Possible links exist among
patients who have a similar social network or have spent
time in the same area (no specific location), without nam-
ing each other as contacts. 
When definite epidemiologic links are found among
cluster members through the review of the TB case registry
and patient records, information is recorded in the database
on the nature of this relationship. If transmission at specif-
ic locations is shown, additional contacts are tested at these
locations. If no such links exist, an epidemiologist reviews
the cases and conducts in-depth patient re-interview to
attempt to identify links and previously unidentified loca-
tions of transmission. A standard questionnaire is used to
re-interview clustered patients. In addition, other registries
such as the Department of Homeless Services are searched
by cross-matching with the database each quarter to iden-
tify other possible exposure locations. 
Performance Indicators
Performance indicators are used to evaluate procedures
with respect to timely shipping of isolates and reporting of
genotyping results and to assess the reliability of genotyp-
ing results. Submission time is calculated for clinical labo-
ratories that process samples from New York City TB
patients as the time between the date a positive culture is
collected and the date the isolate is received at the public
health laboratory. Submission time for genotyping is the
time between the date the isolate is received at the public
health laboratory and the date the isolate is sent for geno-
typing. Reporting time for the genotyping laboratories is
the time between the date the specimen is received at the
genotyping laboratory and the date the spoligotype or
RFLP is reported to the Bureau of Tuberculosis Control. 
The time to completion of investigations of false-posi-
tive cultures is defined as the time from specimen collec-
tion to investigation completion. The goal is to complete
investigations within 90 days of collecting the first positive
culture. Time to completion of a cluster investigation is
calculated from the date a cluster is identified and an
investigation is initiated until a decision is made regarding
links between cases in the cluster; the goal is to complete
these investigations within 21 days. Because clusters are
dynamic, a new investigation is started when an additional
case with that particular strain is identified.
Quality assurance exercises to assess the reliability of
genotyping results are performed every 6 months. Ten per-
cent of isolates genotyped in the previous 6 months are
randomly selected by Bureau of Tuberculosis Control and
sent for blinded retyping. Each laboratory repeats genotyp-
ing and sends the results to the bureau for comparison with
previously reported results. Discrepant results are
reviewed and discussed in the working group, and another
isolate is requested from the initial processing laboratory
to verify results.
Outcomes
The genotyping services process is summarized in the
online Appendix Figure (available at http://www.cdc.gov/
ncidid/EID/vol12no05/05-0446_appG.htm). The number
of eligible isolates by year is shown in the Table. As of
March 2004, isolates for 2,600 (96.8%) of 2,685 patients
with a diagnosis of culture-positive TB from January 1,
2001, to December 31, 2003, were submitted. Of 85
patient isolates not submitted to the public health laborato-
ry, 78.8% were processed at commercial laboratories,
mostly outside of New York City. For patient isolates with
incomplete genotyping (n = 163), RFLP could not be per-
formed because of inadequate growth or overgrowth with
other mycobacteria or fungi. Spoligotype and RFLPresults
were available for 2,437 (93.7%) of the 2,600 isolates sub-
mitted (90.7% of all culture-positive patients). The median
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decreased from 84 days in 2001 to 53 days in 2003, and the
reporting time for RFLP patterns decreased from 127 days
in 2001 to 78 days in 2003 (Figure). Fifty-nine (2.4%) iso-
lates were false-positive cultures; 37% of investigations of
these false-positive cultures were initiated through match-
ing genotyping results or a spoligotype suggestive of con-
tamination with a laboratory TB strain. Outside requests
initiated 8.5% of investigations; 24.0% were initiated from
the single positive culture list, and 30.5% by request from
staff within the Bureau of Tuberculosis Control. The medi-
an time to complete investigations of false-positive cul-
tures decreased from 178 days in 2001 to 85 days in 2003.
In 2003, patients with a false-positive culture were treated
unnecessarily for a median of 7 days (range 0–145). This
median number of days is considerably lower than that
seen before universal genotyping; in 1999, patients identi-
fied by retrospective surveillance (i.e., the single-positive
culture list) as having false-positive cultures completed a
median of 7 months of treatment.
Among 2,378 isolates with a complete genotype (true-
positive cultures), 565 spoligotype patterns and 1,600
RFLP patterns were identified; 2,009 (84.5%) of 2,378
patient isolates clustered in 196 spoligotype clusters, and
1,002 (42.1%) of 2,378 patient isolates in 224 RFLP clus-
ters. Eight hundred thirty-seven (35.2%) of the 2,378 iso-
lates had RFLP and spoligotype patterns that matched >1
other isolate pattern; these isolate patterns were grouped
into 205 genotype clusters ranging in size from 2 to 81
cases (mean 4 cases/cluster; median 2 cases/cluster). The
percentage of clustered patient isolates remained stable
during the 3-year period (χ2 for trend p = 0.3652). While
most patient isolates had 9–13 copies of IS6110 (median
11 copies, range 1–23), strains with a lower copy number
(<6 bands) were more likely to be clustered. From 2001 to
2003, two large outbreaks occurred that involved strains of
1 and 3 IS6110 copies. After these strains were excluded,
the percentage clustered remained higher for patterns with
lower numbers of IS6110. 
A total of 278 (33.2%) of 837 clustered cases had epi-
demiologic links identified; of these, 105 (37.8%) had
links established through traditional contact investigations.
Genotype cluster investigations established links for the
remaining 62%: 15% of the links were definite, 11% prob-
able, and 36% possible. For 66.4% of clustered cases (556
cases), no epidemiologic links were identified. Time to
completion of cluster investigations decreased from a
median of 176 days in 2001 to 37 days in 2003. The delay
in completing investigations at the beginning of the project
was mostly due to staff vacancies. Cluster investigations
uncovered 57 additional links among cases with matching
genotypes and 17 additional sites of transmission. Links
established through genotype cluster investigations led to
4 expanded contact investigations in congregate settings (2
in homeless shelters, 1 in a single-room-occupancy hotel,
and 1 in a local grocery store). These investigations iden-
tified additional infected contacts and 4 additional TB
patients at a homeless shelter. These sites are now moni-
tored closely for additional patient isolates with these
genotypes. Transmission between TB patients was ruled
out in >5 site investigations because the genotypes were
unrelated, avoiding more extensive case-finding efforts
that are needed once transmission is seen.
Four quality assurance exercises were performed from
2001 to 2003 on 216 isolates. The result was 94.4% con-
cordance for spoligotyping and 93.5% for RFLP. Of
retyped spoligotype patterns that did not exactly match the
original patterns, 50% differed by ±1 spacer, 8% differed
in multiple successive spacers, and 42% differed for other
reasons. Among retyped RFLPpatterns, 57% differed from
the original patterns because of the existence or absence of
>1 bands, 36% differed because of pattern shifts, and 7%
differed for other reasons. 
Discussion
We achieved real-time universal genotyping as part of
routine TB control with capture and completion comparable
to that seen by the National Tuberculosis Genotyping and
Surveillance Network sites (30). High participation rates
among clinical laboratories were essential to the complete-
ness of genotyping. Timely submission of isolates from
clinical laboratories and continuing decrease in submission
time from the public health laboratory to the genotyping
laboratories also facilitated efforts to achieve real-time
investigation of false-positive cultures and clusters.
Implementation of TB genotyping in a large TB control
program is complex. It requires TB control, epidemiology,
and laboratory resources, and the costs are substantial.
New York City contracts with genotyping laboratories
carry an annual cost of nearly US $150,000 ($20,000 for
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epidemiologists are allocated for database management
and cluster investigation in New York City. Nonetheless,
we have seen added value from universal genotyping.
Additional sites of transmission were found on the basis of
results of cluster investigations. Expanded investigations
conducted at these sites identified additional patients and
infected contacts who were subsequently treated for TB
and latent TB infection. Genotyping information has also
been useful by showing that TB cases clustered in place
and time can have unrelated genotypes. For example, unre-
lated genotypes of >2 TB cases diagnosed in a setting with
a high prevalence of TB infection may provide evidence
that the cases did not occur as a result of transmission with-
in that setting. Thus, more limited contact investigations of
persons exposed to each of the patients can be performed
instead of the more aggressive expanded contact investiga-
tion or case-finding activities that would be required if the
isolates had matching genotypes. In addition, the efficien-
cy of investigations of false-positive cultures increased as
a result of universal genotyping, since a greater proportion
of investigations initiated through genotyping matches
yielded true false-positive culture results than investiga-
tions initiated through other methods. The amount of
unnecessary treatment for these patients also decreased.
The higher rates of clustering seen in low copy-number
isolates by RFLPalone support our decision to use 2 geno-
typing assays; this phenomenon has been reported previ-
ously (11). In addition, the rapid availability of spoligotype
results allowed earlier initiation of investigations of both
clusters and false-positive cultures than would have been
possible with RFLP results alone. Particularly useful was
close communication with the Wadsworth Center on inter-
pretation of spoligotype matches for “rare” spoligotypes
(seen less often than average for most spoligotypes in our
database) and on prioritization of these isolates for investi-
gation as clusters or false-positive cultures.
Since January 2004, mycobacterial interspersed repeti-
tive unit and spoligotyping analyses are performed on all
isolates as part of the Centers for Disease Control and
Prevention’s National Tuberculosis Genotyping Program.
The availability of this additional assay will allow us to
examine the extent to which MIRU further differentiates
genotype clusters on the basis of RFLP and spoligotyping.
MIRU may also reduce the time to obtain the genotype
result and initiate a cluster investigation since it, like
spoligotyping, requires few organisms and does not
require live culture. Implementing the national genotyping
service will also greatly reduce the financial costs for TB
control jurisdictions interested in using genotyping to
enhance their current program activities (31).
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